Acasti Pharma

119 articles with Acasti Pharma

• Acasti Intends to Request Hearing Before Nasdaq Panel to Present Plan of Compliance

  5/17/2021

  Acasti Pharma Inc. announced that, on May 11, 2021, the Company received notice from the Nasdaq Listing Qualifications Department indicating that, based upon the Company’s non-compliance with the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550 as of May 10, 2021, the Company’s securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel.

• Acasti Announces Definitive Agreement to Acquire Grace Therapeutics, Inc.

  5/7/2021

  Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) announces it has entered into a definitive agreement to acquire Grace Therapeutics, Inc. (“Grace”), a privately held emerging biopharmaceutical company focused on developing innovative drug delivery technologies for the treatment of rare and orphan diseases (the “Proposed Transaction”).

• Acasti Pharma Provides Update on Recent Financing Activities - Mar 08, 2021

  3/8/2021

  As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. is providing an update on the use of its “at-the market” equity offering program.

• Acasti Pharma Announces Results for Third Quarter of Fiscal 2021

  2/9/2021

  Acasti Pharma Inc. announced its operating and financial results for the third quarter of fiscal 2021 ended December 31, 2020.

• Acasti Pharma Provides Update on Recent Financing Activities

  1/27/2021

  As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) is providing an update on the use of its “at-the market” equity offering program.

• Acasti Pharma Unaware of Any Material Change

  12/23/2020

  At the request of IIROC, Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST) wishes to confirm that the Company’s management and Board of Directors are unaware of any material change in the Company’s operations that would account for the recent increase in market activity. About Acasti Acasti is a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescript

• Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2021

  11/16/2020

  Acasti Pharma Inc. provided a business update and announced its operating and financial results for the second quarter of fiscal 2021 ended September 30, 2020.

• Acasti Announces Review Process of Strategic AlternativesAdditional analyses of TRILOGY data underway

  9/29/2020

  Acasti Pharma Inc. announces the Company has commenced a formal process to explore and evaluate strategic alternatives to enhance shareholder value.

• Acasti Appoints Seasoned Executive Brian D. Ford CPA-CA as Chief Financial Officer

  9/16/2020

  Acasti Pharma Inc. announced that it has appointed seasoned financial executive Brian D. Ford as its Chief Financial Officer, effective September 14, 2020.

• Acasti Announces Filing and Mailing of Information Circular and Change in Record Date

  9/11/2020

  Acasti Pharma Inc. announced that it has filed and mailed the information circular and management proxy statement for its upcoming annual and special meeting of shareholders to be held on September 30, 2020.

• 

  Acasti's CaPre Flunks Phase III Triglyceride Trial

  9/1/2020

  The primary endpoint was triglyceride reduction at 12 and 26 weeks. The trial evaluated 278 patients.

• Acasti Pharma Reports Topline Triglyceride Results from Phase 3 TRILOGY 2 Study of CaPre in Patients with Severe Hypertriglyceridemia

  8/31/2020

  CaPre achieved a 30.4% median reduction in triglycerides at 12 weeks and 38.4% at 26 weeks, but did not achieve statistical significance for the primary endpoint

• Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2021On track to report TRILOGY 2 topline data on or about August 31, 2020

  8/13/2020

  Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (sHTG) (triglyceride blood levels from 500 mg/dL to 1500 mg/dL), today provided a business update and announced its operating and financial results for the first quarter

• Acasti Pharma Submits Statistical Analysis Plan to FDA and Remains On Track to Report TRILOGY 2 Topline Data On or About August 31, 2020

  7/31/2020

  Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia (sHTG) (triglyceride blood levels from 500 mg/dL to 1500 mg/dL), today announced it has completed its revisions to the pre-specified Statistical Analysis Plan (SAP) f

• Acasti Pharma Provides Fiscal 2020 Year-End Business Update

  6/29/2020

  Identifies “Triglyceride Normalization” phenomenon prior to patient randomization and treatment  as likely contributor to unusually high placebo effect in TRILOGY 1 Acasti management to host conference call at 1 PM ET today LAVAL, Quebec, June 29, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre ® (omega

• Acasti Pharma Receives FDA Response to TRILOGY 1 Briefing PackagePlans to report summary of Trilogy 1 data on June 29, 2020 conference call

  6/19/2020

  Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that the FDA has provided Acasti with a written response to its Type C Meeting request and briefing package. The FDA confirmed that it will require piv

• Acasti Pharma Announces Submission of TRILOGY 1 Briefing Package to FDA

  4/30/2020

  FDA response expected on or before June 30, 2020 Acasti also received notice of issuance of a Composition of Matter Patent in Hong Kong

• Acasti Pharma Awarded Notice of Allowance for Second Composition of Matter Patent in CanadaExpands existing claims to include any omega-3 phospholipid containing at least 50% phospholipids

  4/20/2020

  Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it has received a Notice of Allowance for its second composition matter patent to be awarded by the Canadian Intellectual Property Office. This ne

• Acasti Pharma Submits FDA Meeting Request on Schedule, and FDA Meeting Expected in the Second Half of June

  4/1/2020

  Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and   commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it has filed its meeting request with the Food and Drug Administration (FDA). The meeting is intended to discuss TRILOGY 1 data, and gain alignm

• Acasti Pharma Awarded Notice of Allowance for Additional Composition of Matter and Method of Use Patents in the United States and Mexico

  3/11/2020

  Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), today announced that it has received a Notice of Allowance for an additional composition of matter and method of use patent from the US Patent and Trademark Office (USPTO)